Paul H Hayashi
Overview
Explore the profile of Paul H Hayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
2436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chalasani N, Hayashi P, Luffer-Atlas D, Regev A, Watkins P
Hepatology
. 2025 Feb;
PMID: 39999469
Drug-induced liver injury (DILI) is rare in clinical practice but when it occurs it can lead to acute liver failure and death. Drug developers and regulators undertake a series of...
2.
Amirzadegan J, Tesfaldet B, Pei Y, Navarro Almario E, Avigan M, Hayashi P
Drug Saf
. 2025 Feb;
PMID: 39932652
Based on the late Dr. Hyman Zimmerman's observation that hepatocellular drug-induced liver injury (DILI) leading to jaundice carries a ≥ 10% fatality risk (coined as Hy's law by others), evaluation...
3.
Ahmad J, Li Y, Phillips E, Dellinger A, Hayashi P, Chalasani N, et al.
Liver Int
. 2025 Jan;
45(2):e16242.
PMID: 39803998
Background And Aims: Short courses of intravenous (iv) methylprednisolone (MP) can cause drug induced liver injury (DILI). The aim of this study was to assess the clinical features and HLA...
4.
Barritt 4th A, Hayashi P, Stolz A, Barnhart H, Hoofnagle J
Am J Gastroenterol
. 2024 Oct;
PMID: 39422332
Introduction: Hyman Zimmerman observed that hepatocellular (HC) drug-induced liver injury (DILI) with jaundice had a mortality rate of ≥ 10% (Hy Law). Hy Law does not specify the timing of...
5.
Fettiplace A, Marcinak J, Merz M, Zhang H, Kikuchi L, Regev A, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(10):1293-1307.
PMID: 39300766
Background: Drug-induced liver injury (DILI) is a major concern for oncology drugs in clinical practice and under development. Monitoring cancer patients for hepatotoxicity is challenging as these patients may have...
6.
Conlon C, Li Y, Ahmad J, Barnhart H, Fontana R, Ghabril M, et al.
Aliment Pharmacol Ther
. 2024 Jul;
60(6):787-795.
PMID: 38988034
Background: Azithromycin (AZ) is a widely used antibiotic. The aim of this study was to characterise the clinical features, outcomes, and HLA association in patients with drug-induced liver injury (DILI)...
7.
Hayashi P, Hoofnagle J
Clin Liver Dis (Hoboken)
. 2024 Jun;
23(1):e0206.
PMID: 38831765
No abstract available.
8.
Pop A, Halegoua-DeMarzio D, Barnhart H, Kleiner D, Avigan M, Gu J, et al.
Dig Dis Sci
. 2024 Feb;
69(4):1479-1487.
PMID: 38416280
Objective: To describe hepatotoxicity due to amiodarone and dronedarone from the DILIN and the US FDA's surveillance database. Methods: Hepatotoxicity due to amiodarone and dronedarone enrolled in the U.S. Drug...
9.
Palmer M, Kleiner D, Goodman Z, Brunt E, Avigan M, Regev A, et al.
Aliment Pharmacol Ther
. 2023 Oct;
59(2):201-216.
PMID: 37877759
Background: Causality assessment of suspected drug-induced liver injury (DILI) during metabolic dysfunction-associated steatohepatitis (MASH) clinical trials can be challenging, and liver biopsies are not routinely performed as part of this...
10.
Asif B, Koh C, Phillips E, Gu J, Li Y, Barnhart H, et al.
J Allergy Clin Immunol Pract
. 2023 Sep;
12(1):168-174.e2.
PMID: 37739311
Background: Intravenous vancomycin therapy can cause liver injury as well as "drug reaction with eosinophilia and systemic symptoms" (DRESS) syndrome. This study aimed to better define the clinical features and...